Unnamed: 0,title,date,stock,sentiment
797271.0,Merrimack Pharmaceuticals Yesterday Reported Q1 EPS $0.020 Up From $(0.780) YoY,2020-05-08 10:48:00-04:00,MACK,neutral
797272.0,Merrimack Pharma Reports Receipt Of $2.25M Related To Closing Of Asset Sale For Preclinical Nanoliposome Programs To Celator Pharma,2020-04-02 08:44:00-04:00,MACK,positive
797273.0,"The Daily Biotech Pulse: Milestone Pharma Flunks Late-Stage Study, CytomX Strikes Cancer Drug Collaboration, BARDA Grant For GenMark's COVID-19 Test",2020-03-24 08:20:00-04:00,MACK,negative
797274.0,"The Daily Biotech Pulse: Mylan Ramps Up Manufacturing Of Potential COVID-19 Drug, Lexicon Stops Study Early, Masimo To Buy German Ventilation Company",2020-03-20 07:44:00-04:00,MACK,negative
797275.0,Stocks That Hit 52-Week Lows On Thursday,2020-03-19 10:49:00-04:00,MACK,negative
797276.0,"The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection",2020-03-19 07:37:00-04:00,MACK,neutral
797277.0,"The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates",2020-03-18 07:36:00-04:00,MACK,positive
797278.0,Stocks That Hit 52-Week Lows On Friday,2020-03-13 11:13:00-04:00,MACK,negative
797279.0,"The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO",2020-03-12 07:37:00-04:00,MACK,negative
797280.0,Stocks That Hit 52-Week Lows On Friday,2020-02-28 10:16:00-05:00,MACK,negative
797281.0,"The Daily Biotech Pulse: Sangamo In Genome-Editing Therapy Deal With Biogen, FDA Nod For Biohaven, Passage Bio IPO",2020-02-28 07:28:00-05:00,MACK,neutral
797282.0,"The Daily Biotech Pulse: Gilead Kicks Off Coronavirus Drug Trials, Adcom Nod For Lily, FDA Approves Esperion's Lipid-Lowering Adjunctive Combo Therapy",2020-02-27 07:35:00-05:00,MACK,positive
797283.0,Stocks That Hit 52-Week Lows On Friday,2020-01-17 13:27:00-05:00,MACK,negative
797284.0,"The Daily Biotech Pulse: Osmotica Soars On Insider Buys, Ultragenyx's Partnered Rare Disease Drug Moves Into Clinics",2020-01-16 07:22:00-05:00,MACK,neutral
797285.0,Stocks That Hit 52-Week Lows On Friday,2019-12-27 11:40:00-05:00,MACK,negative
797286.0,"The Daily Biotech Pulse: Axovant Surges On Gene Therapy Study Results, FDA Approves Merck's Ebola Vaccine, Abeona Announces Offering",2019-12-20 08:12:00-05:00,MACK,positive
797287.0,Stocks That Hit 52-Week Lows On Thursday,2019-12-19 11:02:00-05:00,MACK,negative
797288.0,63 Biggest Movers From Yesterday,2019-12-04 05:15:00-05:00,MACK,neutral
797289.0,Merrimack Declares Special Dividend Of ~$0.50/Share,2019-12-03 08:48:00-05:00,MACK,positive
797290.0,"Merrimack Receives $5M Milestone Payment From Ipsen, Triggered By Ipsen's Decision To Progress Trial Evaluating ONIVYDE",2019-12-03 08:48:00-05:00,MACK,positive
797291.0,"The Daily Biotech Pulse: ChemoCentryx Triples On Data Readout, Global Blood Given FDA Nod, Positive Safety Review For Genfit's NASH Drug",2019-11-26 08:06:00-05:00,MACK,positive
797292.0,Stocks That Hit 52-Week Lows On Monday,2019-11-25 11:15:00-05:00,MACK,negative
797293.0,"The Daily Biotech Pulse: Roche-Spark Deal Extended Again, Zymeworks' Positive Readout, Enanta Misses Earnings Estimate",2019-11-22 08:18:00-05:00,MACK,positive
797294.0,Stocks That Hit 52-Week Lows On Thursday,2019-11-21 11:09:00-05:00,MACK,negative
797295.0,52 Biggest Movers From Friday,2019-09-30 03:39:00-04:00,MACK,neutral
797296.0,JFL Capital Reports Ended Campaign At Merrimack Pharma,2019-09-24 16:49:00-04:00,MACK,neutral
797297.0,"2 Recent 13D Filings On Merrimack Pharma: Western Standard Shows 6.3% Stake, Newtyn Mgmt. Shows 8.8% Stake",2019-09-19 13:16:00-04:00,MACK,neutral
797298.0,58 Biggest Movers From Yesterday,2019-09-13 07:04:00-04:00,MACK,neutral
797299.0,71 Biggest Movers From Yesterday,2019-09-12 05:33:00-04:00,MACK,neutral
797300.0,48 Stocks Moving In Wednesday's Mid-Day Session,2019-09-11 12:27:00-04:00,MACK,neutral
797301.0,"JFL Capital Issues Letter Criticizing Board, Appoints New Nominees",2019-08-22 08:36:00-04:00,MACK,negative
797302.0,"Merrimack Pharma To Reschedule 2019 Annual Shareholder Meeting From Oct. 17, 2019 To Sept. 16, 2019",2019-08-16 09:19:00-04:00,MACK,neutral
797303.0,UPDATE: Merrimack Special Dividend $1.50/Share,2019-07-25 08:31:00-04:00,MACK,positive
797304.0,Merrimack Declares $20M Special Dividend,2019-07-25 08:31:00-04:00,MACK,positive
797305.0,"Merrimack Pharmaceuticals Named New Long Idea At Seven Corners Capital, Firm Sets $10.50 Price Target And Sees 84% Upside; Calls Stock ' Relatively Safe Pharma Play with Significant Upside'",2019-07-16 13:07:00-04:00,MACK,positive
797306.0,"Merrimack Pharmaceuticals President, CEO And Director Richard Peters Resigned From Each Position As Of June 28, 2019",2019-07-01 16:16:00-04:00,MACK,negative
797307.0,"Merrimack Pharma 8-K Shows Amendment For Asset Purchase Deal To Extend Closing Date For Transaction From Jun. 24, 2019 To Jun. 28, 2019",2019-06-24 16:28:00-04:00,MACK,positive
797308.0,"The Daily Biotech Pulse: Merrimack To Stay Independent, Chinese Cheer For Beigene, XBiotech Offering",2019-05-31 07:34:00-04:00,MACK,positive
797309.0,"Merrimack Pharma To Issue Near-Term Special Dividend Between $16.9M-$18.9M If Asset Sale To 14ner Oncology Closes, Between $13.4M-$15.4M If Asset Sale Does Not Successfully Close",2019-05-30 16:13:00-04:00,MACK,positive
797310.0,"Merrimack Pharma Reports Completion Of Strategic Review, Will Implement Series Of Measures To Extend Co.'s Cash Runway Into 2027; 100 Potential Partners Were Contacted, Co. Will Not Move Forward With Any Of Them",2019-05-30 16:12:00-04:00,MACK,positive
797311.0,Merrimack Pharmaceuticals Q1 EPS $(0.78) Up From $(1.33) YoY,2019-05-10 07:44:00-04:00,MACK,neutral
797312.0,Merrimack Pharma 8-K Shows Co. Board Committed To Implement Reduction In Headcount Affecting 13 Employees For Clinical Organization Following Discontinuation Of MM-310 Development,2019-04-30 07:51:00-04:00,MACK,positive
797313.0,54 Biggest Movers From Friday,2019-04-08 05:11:00-04:00,MACK,neutral
797314.0,40 Stocks Moving In Friday's Mid-Day Session,2019-04-05 12:30:00-04:00,MACK,neutral
797315.0,Merrimack Pharmaceuticals shares are trading higher after the company discontinued development of its MM-310 after the safety report showed Phase 1 study was unable to reach optimal therapeutic index.,2019-04-05 08:37:00-04:00,MACK,positive
797316.0,24 Stocks Moving In Friday's Pre-Market Session,2019-04-05 08:05:00-04:00,MACK,neutral
797317.0,"The Daily Biotech Pulse: Merrimack Pulls The Plug On Early-Stage Trial, Legal Headache For Novartis-Amgen Migraine Partnership",2019-04-05 07:48:00-04:00,MACK,positive
797318.0,Merrimack Discontinues Development Of MM-310 After Safety Update Showed Phase 1 Study Was Unable To Reach Optimal Therapeutic Index; Co. Plans To Reduce Workforce Reflective Of Narrowed Preclinical Development Pipeline,2019-04-04 16:17:00-04:00,MACK,positive
797319.0,Merrimack Pharmaceuticals Earlier Announced Restructuring Which Includes Workforce Reduction Of Approximately 60%,2018-11-07 09:50:00-05:00,MACK,neutral
797320.0,"The Daily Biotech Pulse: FDA Nod For Bristol-Myers Squibb, Momenta Strikes Patent License Deal With AbbVie",2018-11-07 07:50:00-05:00,MACK,negative
797321.0,"Merrimack Pharmaceuticals, Inc. Q3 EPS From Continuing Operations $(0.92)",2018-11-07 06:52:00-05:00,MACK,neutral
797322.0,"Merrimack Pharmaceuticals, Inc. Q3 EPS $0.30 MAy Not Compare To $(0.27) Estimate",2018-11-07 06:51:00-05:00,MACK,neutral
797323.0,Merrimack Pharmaceuticals Q3 Earnings Preview,2018-11-06 13:44:00-05:00,MACK,neutral
797324.0,"The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs",2018-11-04 13:35:00-05:00,MACK,neutral
797325.0,58 Biggest Movers From Friday,2018-10-22 05:11:00-04:00,MACK,neutral
797326.0,Mid-Afternoon Market Update: NASDAQ Turns Lower; Bank OZK Shares Plummet,2018-10-19 14:52:00-04:00,MACK,neutral
797327.0,42 Stocks Moving In Friday's Mid-Day Session,2018-10-19 12:53:00-04:00,MACK,neutral
797328.0,Mid-Day Market Update: Skechers Rises On Upbeat Earnings; Merrimack Pharmaceuticals Shares Slide,2018-10-19 12:04:00-04:00,MACK,positive
797329.0,Merrimack's String of Failures Continues With Lung Cancer Study Shelved After Midstage Trials,2018-10-19 10:48:00-04:00,MACK,negative
797330.0,Mid-Morning Market Update: Markets Open Higher; Procter & Gamble Profit Tops Estimates,2018-10-19 10:17:00-04:00,MACK,positive
797331.0,Merrimack Shares are trading lower after the company announced it would discontinue its Phase 2 SHERLOC study due to 'futility.',2018-10-19 07:51:00-04:00,MACK,neutral
797332.0,Merrimack Discontinues Phase 2 SHERLOC Study of MM-121 in Patients with NSCLC Due to Futility,2018-10-19 06:02:00-04:00,MACK,neutral
797333.0,"Stocks Which Set New 52-Week Low Yesterday, October 11th",2018-10-12 11:30:00-04:00,MACK,negative
797334.0,30 Stocks Moving In Thursday's Pre-Market Session,2018-09-20 08:15:00-04:00,MACK,neutral
797335.0,"Merrimack Receives $5M Milestone Payment from Shire Triggered By The Sale Of ONIVYDE In The First Non-European, Non-Asian Country Pursuant To The Terms Of Merrimack's Asset Sale To Ipsen In 2017",2018-09-20 07:02:00-04:00,MACK,positive
797336.0,Merrimack Reports Completion Of Enrollment In Randomized Phase 2 SHERLOC Study Of MM-121 In Non-Small Cell Lung Cancer,2018-09-06 06:50:00-04:00,MACK,negative
797337.0,"The Daily Biotech Pulse: FDA Snub For Gemphire, Ligand Earnings, Insmed's Antibiotic Faces FDA Panel",2018-08-07 08:23:00-04:00,MACK,negative
797338.0,Merrimack Pharmaceuticals Q2 EPS $(1.33) Misses $(1.28) Estimate,2018-08-07 06:37:00-04:00,MACK,negative
797339.0,Former Akebia and Merrimack Pharmaceuticals Employees Convicted of Insider Trading,2018-07-10 14:58:00-04:00,MACK,neutral
797340.0,Merrimack Secures $25M Debt Facility With Hercules Capital,2018-07-02 16:17:00-04:00,MACK,negative
797341.0,"Benzinga's Daily Biotech Pulse: Pain Therapeutics Drops 70%, Neon To Begin Trading",2018-06-27 08:14:00-04:00,MACK,negative
797342.0,10 Biggest Price Target Changes For Tuesday,2018-06-26 09:51:00-04:00,MACK,neutral
797343.0,"Benzinga's Daily Biotech Pulse: Epidiolex, Roche's Influenza Drug Gets Priority Review Status, Xeris Jumps On Positive Trial Results",2018-06-26 08:34:00-04:00,MACK,positive
797344.0,"Baird Maintains Neutral on Merrimack Pharmaceuticals, Lowers Price Target to $7",2018-06-26 07:56:00-04:00,MACK,negative
797345.0,44 Biggest Movers From Yesterday,2018-06-26 04:50:00-04:00,MACK,neutral
797346.0,Mid-Afternoon Market Update: NASDAQ Down Over 2.5%; Xerium Technologies Shares Spike Higher,2018-06-25 14:32:00-04:00,MACK,positive
797347.0,36 Stocks Moving In Monday's Mid-Day Session,2018-06-25 12:26:00-04:00,MACK,neutral
797348.0,Mid-Day Market Update: Dow Falls 350 Points; Merrimack Pharmaceuticals Shares Plummet,2018-06-25 12:06:00-04:00,MACK,positive
797349.0,Mid-Morning Market Update: Markets Open Lower; Carnival Cuts Profit Forecast,2018-06-25 10:41:00-04:00,MACK,negative
797350.0,JP Morgan Downgrades Merrimack Pharmaceuticals to Underweight,2018-06-25 10:36:00-04:00,MACK,positive
797351.0,Merrimack Plummets 30% After Pancreatic Cancer Drug Doesn't Meet Endpoints,2018-06-25 10:29:00-04:00,MACK,negative
797352.0,"Merrimack Pharma Shares Down 34.3% Premarket After Phase 2 Trial Of MM-141 For Pancreatic Cancer Did Not Meet Primary Or Secondary Endpoints, Company Ceases Development Of MM-141",2018-06-25 09:29:00-04:00,MACK,negative
797353.0,"Merrimack Pharma Phase 2 Trial Does Not Meet primary or Secondary Endpoints, Company Ceases Development of MM-141",2018-06-25 07:21:00-04:00,MACK,neutral
797354.0,"Merrimack Pharma Halted, News Pending",2018-06-25 07:16:00-04:00,MACK,neutral
797355.0,"Merrimack Pharma Shares Resume Trade, Now Up ~17% At $10.23",2018-06-13 13:24:00-04:00,MACK,positive
797356.0,Merrimack Pharma Shares Halted On Circuit Breaker Up 15.1%,2018-06-13 13:19:00-04:00,MACK,positive
797357.0,"UPDATE: Merrimack Pharma Shares Spike ~17% Over Last Few Mins., Now Up 15% For Session; Not Yet Seeing News To Justify Price Spike",2018-06-13 13:19:00-04:00,MACK,positive
797358.0,Merrimack Pharmaceuticals Option Alert: Jul 20 $10 Calls at the Ask: 1100 @ $0.85 vs 16 OI; Earnings 8/8 Before Open [est] Ref=$8.86,2018-06-13 13:18:00-04:00,MACK,positive
797359.0,"Merrimack Shares Spike To High Of $9.27, Now Up ~4.6% At $9.21/Share",2018-06-13 13:17:00-04:00,MACK,positive
797360.0,The Week Ahead In Biotech: ASCO Presentations Dominate The Headlines,2018-06-03 19:27:00-04:00,MACK,negative
797361.0,Merrimack Pharmaceuticals Awarded U.S. Patent For Bi-Specific Fusion Proteins,2018-05-29 10:26:00-04:00,MACK,positive
797362.0,Merrimack Pharmaceuticals Q1 EPS $(1.33) Misses $(1.16) Estimate,2018-05-08 06:29:00-04:00,MACK,negative
797363.0,27 Stocks Moving In Thursday's Pre-Market Session,2018-04-19 08:04:00-04:00,MACK,neutral
797364.0,42 Biggest Movers From Friday,2018-03-26 05:13:00-04:00,MACK,neutral
797365.0,46 Biggest Movers From Yesterday,2018-03-13 05:38:00-04:00,MACK,neutral
797366.0,Merrimack Pharmaceuticals Shares Down 10.1% After Co. Earlier Reported Q4 Loss Wider Than Expected,2018-03-12 15:13:00-04:00,MACK,neutral
797367.0,Mid-Afternoon Market Update: BlueLinx Surges On Cedar Creek Acquisition; Anthera Pharmaceuticals Shares Plunge,2018-03-12 14:33:00-04:00,MACK,positive
797368.0,32 Stocks Moving In Monday's Mid-Day Session,2018-03-12 12:58:00-04:00,MACK,neutral
797369.0,Merrimack Reports Q4 EPS $(0.89) vs $(0.28) Est.,2018-03-12 06:28:00-04:00,MACK,neutral
797370.0,"Earnings Scheduled For March 12, 2018",2018-03-12 04:35:00-04:00,MACK,neutral
797371.0,"The Week Ahead In Biotech: Earnings, PDUFA Dates And More",2018-03-11 16:58:00-04:00,MACK,neutral
797372.0,Merrimack Doses First Patient in Randomized Phase 2 Clinical Study of MM-121 in Patients with Post-Menopausal Metastatic Breast Cancer,2018-02-26 06:55:00-05:00,MACK,negative
797373.0,6 Stocks Moving In Wednesday's After-Hours Session,2017-12-27 17:26:00-05:00,MACK,neutral
797374.0,Merrimack Reports Q3 EPS From Continuing Operations $(0.40) vs $(1.88) Est.,2017-11-08 06:50:00-05:00,MACK,neutral
797375.0,30 Stocks Moving In Monday's Pre-Market Session,2017-10-30 08:05:00-04:00,MACK,neutral
797376.0,A Peek Into The Markets: U.S. Stock Futures Down Ahead Of Consumer Spending Data,2017-10-30 07:13:00-04:00,MACK,neutral
797377.0,Merrimack Receives Orphan Drug Designation from the FDA for MM-121 for the Treatment of Heregulin Positive Non-small Cell Lung Cancer,2017-10-30 06:59:00-04:00,MACK,negative
797378.0,12 Stocks Moving In Tuesday's After-Hours Session,2017-10-10 18:24:00-04:00,MACK,neutral
797379.0,"Merrimack Announces Settlement of Convertible Note Litigation, Will Pay Plaintiffs $0.90 per $1 of Convertible Notes, Commence Tender Offer To Acquire All Remaining Convertible Notes At That Rate Plus Accrued Interest",2017-10-10 16:24:00-04:00,MACK,positive
797380.0,"Merrimack Pharma Reports Date For 1-for-10 Reverse Split: Effective Sept. 6, 2017",2017-08-31 08:03:00-04:00,MACK,positive
797381.0,Merrimack Announces Jean Franchi CFO,2017-08-14 06:55:00-04:00,MACK,neutral
797382.0,Merrimack Pharmaceuticals Holding Shareholder Meeting Today,2017-08-11 08:48:00-04:00,MACK,neutral
797383.0,Merrimack Q2 EPS $(0.03) vs $(0.14) Est.,2017-08-09 06:56:00-04:00,MACK,neutral
797386.0,Merrimack Announces Resignation Of CFO Dr. Yasir Al-Wakeel,2017-05-25 16:31:00-04:00,MACK,negative
797387.0,Merrimack Sees Receiving Up to $33M in Net Milestone Payments within Its Cash Runway,2017-05-10 06:51:00-04:00,MACK,neutral
797388.0,Merrimack Pharma Reports Q1 EPS $(0.23) vs $(0.11) Est.,2017-05-10 06:50:00-04:00,MACK,neutral
797389.0,22 Stocks Moving In Thursday's Pre-Market Session,2017-04-06 08:15:00-04:00,MACK,neutral
797390.0,Merrimack Declares $1.06 Special Dividend,2017-04-05 16:05:00-04:00,MACK,positive
797391.0,Merrimack To Return $140M To Stockholders Through Special Cash Dividend,2017-04-03 11:31:00-04:00,MACK,positive
797392.0,"Merrimack  Launches New Focused Research & Clinical Co., Will Prioritize MM-121, MM-141 and MM-310 As Lead Pipeline Candidates",2017-04-03 11:31:00-04:00,MACK,positive
797393.0,Merrimack Stockholders Approve Sale of ONIVYDE and Generic DOXIL to Ipsent For Up To $1.025B,2017-03-30 12:02:00-04:00,MACK,neutral
797394.0,Merrimack Begins Phase 1 Study of MM-310 in Solid Tumors,2017-03-23 07:02:00-04:00,MACK,positive
797395.0,"Merrimack Shares Spike to Session Highs, Now Up 6% as Traders Circulating Unconfirmed Rehashed Takeover Chatter of Shire Interest",2017-03-16 10:23:00-04:00,MACK,positive
797396.0,"Merrimack Reports Q4 EPS $(0.25) vs $(0.21) Est., Sales $61.24M vs $50.4M Est.",2017-03-01 07:21:00-05:00,MACK,neutral
797397.0,Benzinga's Option Alert Recap From February 3,2017-02-03 16:46:00-05:00,MACK,positive
797398.0,Option Alert: Merrimack Pharm Mar 4.0 Calls Sweep: 500 @  ASK  $0.15: 1000 traded vs 1871 OI:  Earnings 2/23 After Close (est)  $3.14 Ref,2017-02-03 15:55:00-05:00,MACK,positive
797399.0,Merrimack Names Dr. Richard Peters CEO,2017-01-18 07:30:00-05:00,MACK,neutral
797400.0,Merrimack Pharma Is Taking Steps In The Right Direction,2017-01-10 10:36:00-05:00,MACK,neutral
797401.0,Mid-Morning Market Update: Markets Mostly Lower; Global Payments Earnings Beat Views,2017-01-09 10:00:00-05:00,MACK,negative
797402.0,15 Stocks Moving In Monday's Pre-Market Session,2017-01-09 08:22:00-05:00,MACK,neutral
797403.0,"The Market In 5 Minutes: Earnings Results, Conferences, Trump And More",2017-01-09 08:17:00-05:00,MACK,neutral
797404.0,A Peek Into The Markets: U.S. Stock Futures Mostly Lower Ahead Of Fed Speakers,2017-01-09 07:57:00-05:00,MACK,negative
797405.0,Wall Street's M&A Chatter From January 6-8,2017-01-09 06:25:00-05:00,MACK,neutral
797406.0,Merrimack Completes Previously Announced Strategic Pipeline Review,2017-01-08 19:53:00-05:00,MACK,neutral
797407.0,"Merrimack Pharmaceuticals Confirms Sale of Onivyde, Generic Version of Doxil to Ipsen for Up to $1.025B",2017-01-08 19:52:00-05:00,MACK,neutral
797408.0,"Merrimack Near Deal to Sell  Onivyde, Doxil to France's Ipsen for ~$1B; Deal Could be Announced Monday -Reuters",2017-01-08 14:01:00-05:00,MACK,neutral
797409.0,Option Alert: Merrimack Pharma Feb 6.0 Calls Sweep: 989 @  ASK  $0.15: 989 traded vs 209 OI:  Earnings 2/23 After Close (est)  $4.04 Ref,2017-01-03 09:50:00-05:00,MACK,positive
797410.0,Mid-Afternoon Market Update: Crude Oil Down 1.5%; Merus Shares Spike Higher,2016-12-21 14:42:00-05:00,MACK,negative
797411.0,15 Biggest Mid-Day Losers For Wednesday,2016-12-21 13:05:00-05:00,MACK,negative
797412.0,Mid-Day Market Update: InvenSense Climbs After Acquisition News; Merrimack Shares Drop,2016-12-21 12:31:00-05:00,MACK,neutral
797413.0,Mid-Morning Market Update: Markets Edge Lower; Finish Line Misses Q3 Expectations,2016-12-21 09:57:00-05:00,MACK,negative
797414.0,20 Stocks Moving In Wednesday's Pre-Market Session,2016-12-21 08:25:00-05:00,MACK,neutral
797415.0,Merrimack Pharmaceuticals -11.555 @$4.75; Co Stopping Phase 2 HERMIONE study of MM-302,2016-12-21 08:14:00-05:00,MACK,negative
797416.0,A Peek Into The Markets: U.S. Stock Futures Flat Ahead Of Existing-Home Sales Report,2016-12-21 07:54:00-05:00,MACK,neutral
797417.0,"Merrimack Stops Phase 2 Study Of Breast Cancer Drug, Shares Lose 20%",2016-12-21 07:44:00-05:00,MACK,negative
797418.0,Merrimack Decides to Stop Phase 2 HERMIONE study of MM-302,2016-12-21 06:56:00-05:00,MACK,negative
797419.0,"Vetr Upgrades Merrimack Following Earnings, Licensing Rumors",2016-11-29 14:52:00-05:00,MACK,neutral
797420.0,18 Stocks Moving In Friday's Pre-Market Session,2016-11-11 08:21:00-05:00,MACK,neutral
797421.0,The Market In 5 Minutes: Retail Earnings Come Into Focus,2016-11-10 09:01:00-05:00,MACK,neutral
797422.0,Wall Street's M&A Chatter From November 10,2016-11-10 06:29:00-05:00,MACK,neutral
797423.0,"Merrimack Pharmaceuticals Reports Q3 EPS $(0.23) vs. Est. $(0.27), Rev. $28M vs. Est. $39M",2016-11-09 16:03:00-05:00,MACK,neutral
797424.0,Option Alert: MACK Nov16 6.0 Calls Sweep: 1620 @  ASK  $0.55: 1692 traded vs 1424 OI:  Earnings today After Close  $5.78 Ref,2016-11-09 10:04:00-05:00,MACK,positive
797425.0,"Merrimack Reviews Strategic Alternatives, Possible Asset Sale",2016-11-09 10:01:00-05:00,MACK,positive
797426.0,Merrimack Reports  Acceptance for Review of ANDA filed by Actavis for Generic Doxorubicin Hydrochloride Liposome Injection,2016-10-31 07:34:00-04:00,MACK,positive
797427.0,18 Biggest Mid-Day Gainers For Tuesday,2016-10-18 12:42:00-04:00,MACK,neutral
797428.0,16 Stocks Moving In Tuesday's Pre-Market Session,2016-10-18 08:37:00-04:00,MACK,neutral
797429.0,Shire Granted EU Marketing Authorization of Onivyde in Combination With 5-Fluorouracil and Leucovorin for Treatment of Metastatic Adenocarcinoma of the Pancreas in Adult Patients Who Have Progressed Following Gemcitabine-Based Therapy,2016-10-18 04:08:00-04:00,MACK,positive
797430.0,"Merrimack Pharma Shares Quiet, Remain Near Session Lows; Hearing Agora Newsletter Recommendation Suggests Name Could Be 'Prime Candidate' for Short Squeeze",2016-10-12 12:42:00-04:00,MACK,positive
797431.0,14 Stocks Moving In Tuesday's Pre-Market Session,2016-10-11 08:33:00-04:00,MACK,neutral
797432.0,Merrimack Pharmaceuticals Reports Overall Survival and PFS Benefit Of ONIVYDE For Pancreatic Cancer Patients,2016-10-11 07:33:00-04:00,MACK,negative
797433.0,4 Reasons JPMorgan Just Downgraded Merrimack Pharmaceuticals,2016-10-07 13:30:00-04:00,MACK,neutral
797434.0,18 Biggest Mid-Day Losers For Friday,2016-10-07 13:16:00-04:00,MACK,negative
797435.0,Merrimack Pharmaceuticals Falls Back To Support Following JPMorgan Downgrade,2016-10-07 10:41:00-04:00,MACK,positive
797436.0,Benzinga's Top Downgrades,2016-10-07 09:09:00-04:00,MACK,positive
797437.0,JP Morgan Downgrades Merrimack Pharmaceuticals to Neutral,2016-10-07 08:34:00-04:00,MACK,positive
797438.0,18 Stocks Moving In Friday's Pre-Market Session,2016-10-07 08:29:00-04:00,MACK,neutral
797439.0,10 Biggest Mid-Day Losers For Monday,2016-10-03 13:32:00-04:00,MACK,negative
797440.0,18 Stocks Moving In Monday's Pre-Market Session,2016-10-03 08:30:00-04:00,MACK,neutral
797441.0,"Merrimack Pharma Shares Resume Trade, Now Down 9%",2016-10-03 07:53:00-04:00,MACK,positive
797442.0,Merrimack Pharmaceuticals to Resume Trading @7:45 AM ET,2016-10-03 07:23:00-04:00,MACK,neutral
797443.0,UPDATE: Merrimack Names Gary Crocker Interim CEO,2016-10-03 07:16:00-04:00,MACK,neutral
797444.0,"Merrimack To Reduce Workforce By 22%, Eliminating $200M In Costs Over Next 2 Years; Accepts CEO Robert Mulroy's Resignation Effective Immediately",2016-10-03 07:15:00-04:00,MACK,positive
797445.0,Merrimack Pharmaceuticals Halted; Pending News,2016-10-03 07:14:00-04:00,MACK,neutral
797446.0,Watch These Huge Call Purchases In Monday Trade,2016-10-03 02:45:00-04:00,MACK,positive
797447.0,Option Alert: MACK Oct16 7.0 Calls Sweep: 1865 @  ASK  $0.35: 2366 traded vs 785 OI:  Earnings 11/14  $6.34 Ref,2016-09-30 11:30:00-04:00,MACK,positive
797448.0,Merrimack To Present Final NAPOLI-1 Phase 3 Results At European Society For Medical Oncology 2016 Congress,2016-09-28 16:12:00-04:00,MACK,neutral
797449.0,Watch These 7 Huge Call Purchases In Tuesday Trade,2016-09-27 02:51:00-04:00,MACK,positive
797450.0,Option Alert: MACK Oct16 6.0 Calls: 1193 @  ASK  $0.95: 1809 traded vs 2457 OI:  Earnings 11/14  $6.57 Ref,2016-09-26 13:35:00-04:00,MACK,positive
797451.0,20 Stocks Which Rallied Three Days On Increasing Volume,2016-09-23 09:19:00-04:00,MACK,neutral
797452.0,Technical Alert - Merrimack Pharmaceutics On Two-Day Run,2016-09-22 14:16:00-04:00,MACK,positive
797453.0,Expect Merrimack Pharma Shares To Be Range-Bound For The Near Term,2016-08-19 09:22:00-04:00,MACK,positive
797454.0,Benzinga's Top Initiations,2016-08-19 09:16:00-04:00,MACK,positive
797455.0,BTIG Research Initiates Coverage on Merrimack Pharmaceuticals at Neutral,2016-08-19 07:57:00-04:00,MACK,neutral
797456.0,"Merrimack Reports Q2 EPS $(0.40) vs. Est. $(0.33), Rev. $33.6M vs. Est. $30.9M",2016-08-04 16:47:00-04:00,MACK,neutral
797457.0,Merrimack Pharma Shares Spike Higher as Hearing CNBC's Jon Najarian Has Purchased Stock for His Model Portfolio,2016-07-29 09:47:00-04:00,MACK,positive
797458.0,Option Alert: MACK Aug16 6.0 Calls Sweep: 1840 @  ASK  $0.25: 2032 traded vs 920 OI:  Earnings 8/4 After Close  $5.52 Ref,2016-07-28 14:34:00-04:00,MACK,positive
797459.0,13 Stocks Moving In Monday's Pre-Market Session,2016-07-25 08:25:00-04:00,MACK,neutral
797460.0,Merrimack Announces ONIVYDE Regimen Receives Positive CHMP Opinion in EU,2016-07-25 04:12:00-04:00,MACK,positive
797461.0,Merrimack Pharma Reports FDA Granted Fast Track Designation for MM-121 in Non-Small Cell Lung Cancer,2016-07-06 08:00:00-04:00,MACK,negative
797462.0,NAPOLI-1 Data Shows ONIVYDE Regimen Maintains Quality of Life While Improving Overall Survival in Patients with Metastatic Pancreatic Cancer,2016-06-30 08:03:00-04:00,MACK,negative
797463.0,Merrimack to Present New Analyses of Phase 3 NAPOLI-1 Data During ESMO 18th World Congress On Gastrointestinal Cancer,2016-06-21 16:32:00-04:00,MACK,negative
797464.0,Merrimack Pharmaceuticals Reports Potential Broad Effect Of MM-151 Across EGFR-Refractory & Naive Populations,2016-06-06 07:32:00-04:00,MACK,negative
797465.0,Baird Initiates Coverage on Merrimack Pharmaceuticals at Neutral,2016-05-26 17:06:00-04:00,MACK,neutral
797466.0,"Merrimack, Baxalta Report Initiation of Phase 1 Study of MM-151 in Combo with ONIVYDE Regimen for Metastatic Colorectal Cancer",2016-05-19 07:18:00-04:00,MACK,negative
797467.0,Merrimack Will Present Extensive Oncology Pipeline at ASCO,2016-05-18 17:12:00-04:00,MACK,neutral
797468.0,UPDATE: Merrimack Says Data from MM-121 Phase 2 Shows 'presence of heregulin may increase risk of progression on exemestane alone in 45% of breast cancer patients tested',2016-05-17 16:11:00-04:00,MACK,negative
797469.0,Merrimack Reports Expanded Analysis Of Seribantumab Reduced Risk of Death In 50% Of HER2-Negative Hormone Receptor Positive Breast Cancer Patients,2016-05-17 16:06:00-04:00,MACK,negative
797470.0,"Merrimack Pharma Reports Q1 EPS $(0.33) Vs Est $(0.38), Sales $21.3M Vs Est $24.16M",2016-05-02 16:03:00-04:00,MACK,neutral
797471.0,Merrimack Pharma Launches MM-310 at AACR,2016-04-21 08:06:00-04:00,MACK,neutral
797472.0,Leica Biosystems and Merrimack Pharmaceuticals to Collaborate on Development of a Heregulin Companion Diagnostic for Seribantumab,2016-04-14 16:07:00-04:00,MACK,neutral
797473.0,Merrimack Reports Inclusion of ONIVYDE as Category 1 Treatment Option in '16 NCCN Guidelines for Pancreatic Adenocarcinoma,2016-03-24 07:06:00-04:00,MACK,neutral
797474.0,"Dir Porter Buys 5,000 Shares of Merrimack Pharmaceuticals @$7.65/Share -Form 4",2016-03-17 10:53:00-04:00,MACK,positive
797475.0,"Director Porter Buys 10,000 Shars of Merrimack Pharmaceuticals @$7.09/Share -Form 4",2016-03-10 09:31:00-05:00,MACK,neutral
797476.0,"Director Porter Buys 15,000 Shares of Merrimack Pharmaceuticals",2016-03-04 09:04:00-05:00,MACK,positive
797477.0,"Dir Porter Buys 20,000 Shares Of Merrimack Pharmaceuticals @$6.11/Share -Form 4",2016-03-02 11:14:00-05:00,MACK,positive
797478.0,"VP McClements Buys 2,000 SharesOf Merrimack Pharmaceuticals @$5.72/Share -Form 4",2016-03-01 13:56:00-05:00,MACK,neutral
797479.0,"Director Lee Buys 35,000 Shares Of Merrimack Pharmaceuticals @$5.50/Share -Form 4",2016-02-29 15:06:00-05:00,MACK,positive
797480.0,"Merrimack Reports Q4 EPS $(0.41) vs. Est. $(0.31), Rev. $21.4M vs. Est. $26.58M",2016-02-25 16:02:00-05:00,MACK,neutral
797481.0,Merrimack Shares Falling,2016-01-12 10:45:00-05:00,MACK,positive
797482.0,Merrimack Amends MM-121 Phase 2 Clinical Study in Heregulin-Positive Non-Small Cell Lung Cancer to Support Potential Registration,2015-12-22 16:17:00-05:00,MACK,negative
797483.0,Merrimack and Baxalta Announce Publication of the ONIVYDE™ (irinotecan liposome injection) NAPOLI-1 Study in The Lancet,2015-11-23 08:03:00-05:00,MACK,neutral
797484.0,"Merrimack Pharma Reports Q3 EPS ($0.38) Vs Est ($0.40), Sales $16.4M Vs Est $14.04M",2015-11-09 16:03:00-05:00,MACK,neutral
797485.0,PharmaEngine Announces FDA Approves Merrimack's ONIVYDE,2015-10-23 04:22:00-04:00,MACK,positive
797486.0,Merrimack Comfirms U.S. FDA Approval of ONIVYDE(TM) (irinotecan liposome injection) for the Treatment of Patients with Metastatic Pancreatic Cancer,2015-10-22 13:12:00-04:00,MACK,negative
797487.0,"FDA Had Granted Priority Review, Orphan Drug Designations for Merrimack's Onivyde",2015-10-22 11:37:00-04:00,MACK,positive
797488.0,"FDA OK's Merrimack's Onivyde in Combination with Fluorouracil, Leucovorin; Approves Merrimack Pharma's Onivyde for Advanced Pancreatic Cancer",2015-10-22 11:36:00-04:00,MACK,negative
797489.0,Merrimack Gets FDA Approval for Advanced Pancreatic Cancer Treatment -Reuters,2015-10-22 11:33:00-04:00,MACK,negative
797490.0,Merrimack Pharma. Shares Halted News Pending,2015-10-22 11:23:00-04:00,MACK,positive
797491.0,Merrimack Pharma Could Have FDA Approval Coming; These Analysts Are Buying,2015-10-06 10:38:00-04:00,MACK,positive
797492.0,10 Biotech Stocks With Catalysts Coming Soon,2015-08-20 12:19:00-04:00,MACK,neutral
797493.0,"Merrimack Pharmaceuticals Director Porter Buys 20,000 Shares @$10.16/Share -Form 4",2015-08-13 08:34:00-04:00,MACK,positive
797494.0,"Oppenheimer Assumes Merrimack Pharmaceuticals at Outperform, Announces $13.00 PT",2015-08-12 07:40:00-04:00,MACK,neutral
797495.0,Merrimack Pharma. Reports Q2 EPS $(0.21) vs. Est. $(0.31),2015-08-10 16:39:00-04:00,MACK,neutral
797496.0,Merrimack Pharma Names Dr. Yasir Al-Wakeel CFO,2015-08-06 08:18:00-04:00,MACK,neutral
797497.0,Option Alert: Merrimack Jul $13 Call Sweep; 1165 Contracts @Ask @$0.40,2015-06-30 11:51:00-04:00,MACK,positive
797498.0,US Stock Futures Surge Ahead Of Jobless Claims,2015-06-25 08:10:00-04:00,MACK,neutral
797499.0,U.S. FDA Grants Priority Review for MM-398 New Drug Application,2015-06-25 07:05:00-04:00,MACK,positive
797500.0,"Merrimack Pharmaceuticals Announces the Addition of John M. Dineen, Former CEO Of GE Healthcare, To Board",2015-06-15 16:10:00-04:00,MACK,neutral
797501.0,Merrimack Pharmaceuticals Reports Expansion of MM-398 (nal-IRI) Imaging Study to Patients with Metastatic Breast Cancer,2015-06-11 17:00:00-04:00,MACK,negative
797502.0,Merrimack Forms A Major Topping Pattern,2015-06-10 10:36:00-04:00,MACK,neutral
797503.0,Merrimack Pharmaceuticals Reports Data from an Investigator-Sponsored Phase 1 Study Showing Acceptable Safety Profile for MM-398 in High-Grade Glioma,2015-06-01 16:13:00-04:00,MACK,positive
797504.0,PharmaEngine Announces Filing NDA of MM-398 to Taiwan FDA as Treatment for Post-Gemcitabine Metastatic Pancreatic Cancer,2015-06-01 04:24:00-04:00,MACK,negative
797505.0,"Merrimack Pharmaceuticals Director Porter Buys 8,284 Shares @$11.79/Share -Form 4",2015-05-15 07:57:00-04:00,MACK,positive
797506.0,Benzinga's Top Initiations,2015-05-13 09:17:00-04:00,MACK,positive
797507.0,Guggenheim Securities Initiates Merrimack Pharmaceuticals With Buy,2015-05-13 09:08:00-04:00,MACK,positive
797508.0,"Guggenheim Securities Initiates Coverage on Merrimack Pharmaceuticals at Buy, Announces $15.00 PT",2015-05-13 06:10:00-04:00,MACK,positive
797509.0,Merrimack Pharma Earlier Reported Q1 Loss of $0.32/Share vs Loss of $0.28/Share Est.,2015-05-07 17:14:00-04:00,MACK,negative
797510.0,Merrimack Pharmaceuticals Reports Initiation of a Phase 2 Front-line Clinical Trial of MM-141 in Biomarker-Selected Patients with Metastatic Pancreatic Cancer,2015-05-05 08:00:00-04:00,MACK,negative
797511.0,"Baxter Bioscience, Merrimack Pharma Report Filing of European Approval for MM-398",2015-05-04 09:02:00-04:00,MACK,positive
797512.0,These 10 Stocks Could Move Big On Monday,2015-05-02 13:18:00-04:00,MACK,neutral
797513.0,PharmaEngine Announces Merrimack Completed MM-398 NDA Submission to U.S. FDA,2015-04-27 21:10:00-04:00,MACK,neutral
797514.0,"Merrimack Pharma, Baxter BioScience Report Closing of NDA Submission to FDA for MM-398 for Treatment of Post-Gemcitabine Metastatic Pancreatic Cancer",2015-04-27 07:01:00-04:00,MACK,negative
797515.0,First-in-Human Phase 1 Trial of MM-141 Demonstrates Activity in Biomarker Positive Patients,2015-04-21 08:03:00-04:00,MACK,positive
797516.0,"Mizuho Securities Maintains Buy on Merrimack Pharmaceuticals, Raises PT to $16.00",2015-04-21 05:02:00-04:00,MACK,positive
797517.0,Merrimack Pharma Reports Final Clinical Results for MM-302 Phase 1 Study,2015-04-20 16:01:00-04:00,MACK,neutral
797518.0,Option Alert: Merrimack Pharma May $13 Call; 3260 Contract Trade at Ask @$0.80; Now $12.39,2015-04-10 09:38:00-04:00,MACK,positive
797519.0,"QuickLogic, Sonic Corp, BioMarin Pharmaceutical Lead Wednesday's After-Hours Movers",2015-04-01 21:31:00-04:00,MACK,neutral
797520.0,Hearing Merrimack CEO Coming Up on CNBC After 2:00 PM ET,2015-04-01 12:23:00-04:00,MACK,neutral
797521.0,"Merrimack Pharmaceuticals Director Porter Buys 5,000 Shares @$11.77/Share -Form 4",2015-03-24 09:16:00-04:00,MACK,positive
797522.0,"After-Hours Movers Led By Pioneer Energy, Weibo & Habit Restaurants",2015-03-10 18:09:00-04:00,MACK,positive
797523.0,"Merrimack Pharma Reports Q4 EPS -$0.09 Vs Est -$0.19; Expects to Start Clinical Trials of MM-398, MM-141 in Front-Line Pancreatic Cancer in 2015; Expects Completion of NDA Submission to FDA for MM-398 in Late 1Q/Early 2Q 2015",2015-02-26 07:10:00-05:00,MACK,negative
797524.0,Merrimack Pharmaceuticals Announces Initiation of a Phase 2 Biomarker-Selected Clinical Trial MM-121,2015-02-19 08:14:00-05:00,MACK,neutral
797525.0,"Merrimack Pharma Offers Added Date Showing Support for MM-141, MM-151 for Pancreatic, Colorectal Cancer, Respectively",2015-01-20 08:07:00-05:00,MACK,negative
797526.0,Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 3,2015-01-13 10:58:00-05:00,MACK,neutral
797527.0,"Merrimack Pharmaceuticals Director Lee Buys 20,000 Shares @$10.23/Share -Form 4",2014-12-23 13:37:00-05:00,MACK,positive
797528.0,"Merrimack Pharmaceuticals Director Porter Buys 8,000 Shares @$8.71/Share -Form 4",2014-12-04 12:16:00-05:00,MACK,positive
797529.0,Merrimack Pharma Reports FDA Fast Track Designation for MM-398 in Post-Gemcitabine Metastatic Pancreatic Cancer,2014-11-19 08:05:00-05:00,MACK,negative
797530.0,"Merrimack Pharmaceuticals Director Porter Buys 5,000 Shares @$8.29/Share -Form 4",2014-11-18 17:11:00-05:00,MACK,positive
797531.0,"Merrimack Pharmaceuticals Chairman Crocker Buys 14,390 Shares @$8.47/Share -Form 4",2014-11-14 10:13:00-05:00,MACK,positive
797532.0,"Merrimack Pharmaceuticals Director Porter Buys 40,000 Shares @$8.37/Share -Form 4",2014-11-13 09:52:00-05:00,MACK,positive
797533.0,"Merrimack Pharmaceuticals, Inc. Reports Q3 EPS of $(0.27) vs $(0.12) Est; Revenue of $28.0M vs $21.79M Est",2014-11-10 16:14:00-05:00,MACK,neutral
797534.0,Merrimack Pharmaceuticals Announces Initiation Of Phase 1 Clinical Study Of MM-398 For Brain Cancer ,2014-11-06 08:35:00-05:00,MACK,negative
797535.0,FDA Grants Orphan Drug Designation To Merrimack Pharmaceuticals' MM-141 For The Treatment of Pancreatic Cancer,2014-11-05 09:01:00-05:00,MACK,negative
797536.0,Top 5 Biotech Stocks Over The Past Year,2014-10-06 14:28:00-04:00,MACK,positive
797537.0,Merrimack Pharmaceuticals Presents Additional Phase 2 Biomarker Data Further Strengthening The Finding That MM-121 Increases Progression Free Survival In Patients With Biomarker Positive Metastatic Breast Cancer,2014-09-30 08:04:00-04:00,MACK,positive
797538.0,"PharmaEngine, Merrimack Amend MM-398 License Agreement ",2014-09-26 05:14:00-04:00,MACK,positive
797539.0,Stocks Gain While Dollar Reaches Highest Level Since 2010,2014-09-24 17:03:00-04:00,MACK,positive
797540.0,Dow Jumps 170 Points; Bed Bath & Beyond Shares Rise On Upbeat Results,2014-09-24 15:54:00-04:00,MACK,positive
797541.0,U.S. Stocks Rise; Accenture Shares Decline On Weak Forecast,2014-09-24 13:17:00-04:00,MACK,negative
797542.0,Markets Edge Lower; KB Home Posts Downbeat Results,2014-09-24 10:49:00-04:00,MACK,negative
797543.0,Morning Market Movers ,2014-09-24 09:40:00-04:00,MACK,neutral
797544.0,Benzinga's Top #PreMarket Gainers,2014-09-24 08:05:00-04:00,MACK,positive
797545.0,Merrimack Shares Rise 21% Premarket on Licensing Deal with Baxter,2014-09-24 07:29:00-04:00,MACK,positive
797546.0,Baxter And Merrimack Pharmaceuticals Enter Into Exclusive Ex-U.S. Licensing Agreement to Develop And Commercialize Novel Cancer Compound MM-398,2014-09-24 07:01:00-04:00,MACK,positive
797547.0,"Cantor Initiates Coverage on Six Pharma Stocks, Each with Buy",2014-09-08 17:36:00-04:00,MACK,neutral
797548.0,"3 Cheap Biotech Stocks Analysts Love: Ohr Pharmaceutical Inc, Merrimack & Amicus",2014-09-08 14:25:00-04:00,MACK,positive
797549.0,Merrimak Pharma Announces Initiation of MM-302 Study,2014-08-11 07:06:00-04:00,MACK,neutral
797550.0,"Merrimack Pharmaceuticals, Inc. Reports Q2 EPS of $(0.17) Which May Not Compare $(0.30) Est; Revenue of $27.80M Which May Not Compare $11.02M Est",2014-08-11 07:03:00-04:00,MACK,neutral
797551.0,4 Biotech Stocks Worth A Look Ahead Of FDA Approvals,2014-07-03 10:36:00-04:00,MACK,positive
797552.0,Sub $10 Stocks With High Institutional & Insider Ownership: Investment Idea Of The Day,2014-06-26 13:34:00-04:00,MACK,neutral
797553.0,UPDATE: Merrimack's NAPOLI-1 Study of MM-398 Showed Significant Improvement in Overall Survival; Co Plans NDA in '14,2014-06-25 16:09:00-04:00,MACK,positive
797554.0,Merrimack Pharma Announces Positive Results From Phase 3 NAPOLI-1 Study,2014-06-25 16:07:00-04:00,MACK,positive
797555.0,"After-Hours Movers: FDO, APP Higher, SWHC, ORCL, MACK Lower",2014-06-19 16:45:00-04:00,MACK,negative
797556.0,"Merrimack Pharmaceuticals Reaches Agreement With Sanofi, Regains Rights to Develop And Commercialize MM-121 ",2014-06-19 16:16:00-04:00,MACK,positive
797557.0,Merrimack Pharma Will Present Added Data Results in Phase 3 NAPOLI-q Study at ESMO,2014-06-17 08:03:00-04:00,MACK,neutral
797558.0,Benzinga's Top #PreMarket Gainers,2014-06-04 08:08:00-04:00,MACK,positive
797559.0,Merrimack Pharmaceuticals Presents Phase 1 Clinical Data Supporting Four Novel Antibody Therapeutic Programs at the 2014 ASCO Annual Meeting ,2014-06-02 16:01:00-04:00,MACK,positive
797560.0,Merrimack Pharma Has Identified Heregulin as Patient Response Biomarker for MM-121,2014-06-02 08:02:00-04:00,MACK,neutral
797561.0,"Merrimack Pharmaceuticals Chairman Crocker Buys 4,000 Shares @$6.69/Share -Form 4",2014-05-22 11:45:00-04:00,MACK,positive
797562.0,"Merrimack Pharmaceuticals Chairman Crocker Buys 9,400 Shares @$6.68/Share -Form 4",2014-05-20 09:55:00-04:00,MACK,positive
797563.0,"Merrimack Pharmaceuticals Director Porter Buys 15,000 Shares @$6.49/Share -Form 4",2014-05-16 14:29:00-04:00,MACK,positive
797564.0,"Merrimack Pharmaceuticals Director Nash Buys 15,000 Shares @$6.79/Share -Form 4",2014-05-09 10:59:00-04:00,MACK,positive
797565.0,"Merrimack Pharmaceuticals Chairman Crocker Buys 17,500 Shares @$6.89/Share -Form 4",2014-05-07 13:21:00-04:00,MACK,positive
797566.0,"PharmaEngine, Merrimack, Announce MM-398 in Combination with 5-FU/LV Met Primary Endpoint of Overall Survival in Phase 3 Post-Gemcitabine Metastatic Pancreatic Cancer Study ",2014-05-02 05:46:00-04:00,MACK,negative
797567.0,Market Wrap For May 1: Markets Mixed To Start The New Month,2014-05-01 16:35:00-04:00,MACK,neutral
797568.0,Mid-Afternoon Market Update: Markets Turn Back As Meritor Hangs Onto Its Gains,2014-05-01 15:22:00-04:00,MACK,positive
797569.0,Mid-Day Market Update: Weight Watchers Shares Surge On Upbeat Results; JDS Uniphase Tumbles,2014-05-01 12:22:00-04:00,MACK,positive
797570.0,"Cowen & Company Upgrades Merrimack Pharmaceuticals, Inc. to Outperform",2014-05-01 11:37:00-04:00,MACK,neutral
797571.0,Mid-Morning Market Update: Markets Mixed; Viacom Posts Upbeat Earnings,2014-05-01 10:32:00-04:00,MACK,neutral
797572.0,Morning Market Movers ,2014-05-01 09:37:00-04:00,MACK,neutral
797573.0,Benzinga's Top #PreMarket Gainers,2014-05-01 08:08:00-04:00,MACK,positive
797574.0,Merrimack Pharmaceuticals MM-398 Achieves Primary Endpoint of Overall Survival in Phase 3 Trial in Post-Gemcitabine Metastatic Pancreatic Cancer ,2014-05-01 06:08:00-04:00,MACK,negative
797575.0,Merrimack Announces Preliminary Data From Pilot Diagnostic Imaging Study of MM-398 ,2014-04-08 08:01:00-04:00,MACK,neutral
797576.0,"After-Hours Movers: BV, SWHC, AVAV, CTIC Moving Higher, HCI, BOBE, CHEF, THOR Lower",2014-03-04 17:24:00-05:00,MACK,negative
797577.0,Merrimack Pharma Files Mixed Securities Shelf Up to $200M,2014-03-04 16:35:00-05:00,MACK,positive
797578.0,"Merrimack Pharmaceuticals, Inc. Reports Q4 EPS of $(0.33) vs $(0.29) Est",2014-02-27 16:05:00-05:00,MACK,neutral
797579.0,Preclinical Study Results of Merrimack's MM-141 Published in Molecular Cancer Therapeutics,2014-02-18 08:06:00-05:00,MACK,negative
797580.0,Merrimack Announces Encouraging Clinical Data From Expanded Phase 1 Study of MM-302 for the Treatment of Advanced HER2-Positive Breast Cancer,2013-12-13 08:36:00-05:00,MACK,neutral
797581.0,"Director Quigley Buys 39,000 Shares of Merrimack Pharmaceuticals -Form 4",2013-12-09 12:17:00-05:00,MACK,positive
797582.0,Benzinga's Top #PreMarket Gainers,2013-12-02 08:38:00-05:00,MACK,positive
797583.0,"Merrimack, Actavis Announce Nanotechnology Collaboration ",2013-11-26 07:08:00-05:00,MACK,neutral
797584.0,"Merrimack Pharmaceuticals, Inc. Reports Q3 EPS of $(0.39) vs $(0.31) Est; Revenue of $6.86M vs $15.45M Est",2013-11-07 07:23:00-05:00,MACK,neutral
797585.0,Stocks Hitting 52-Week Lows,2013-10-30 10:13:00-04:00,MACK,negative
797586.0,Benzinga's Top #PreMarket Losers,2013-10-30 08:29:00-04:00,MACK,negative
797587.0,Merrimack Pharmaceuticals Announces Phase 2 Study Of MM-121 Misses Primary Endpoint,2013-10-30 06:04:00-04:00,MACK,negative
797588.0,"PharmaEngine,  Merrimack Achieve Patient Enrollment Goal in Phase III Metastatic Pancreatic Cancer Study of PEP02",2013-08-29 05:57:00-04:00,MACK,negative
797589.0,Stocks Hitting 52-Week Lows,2013-08-14 10:34:00-04:00,MACK,negative
797590.0,Merrimack Pharm Wins Orphan Drug Status for MM-111,2013-08-13 08:02:00-04:00,MACK,positive
797591.0,Benzinga's Top Pre-Market Gainers,2013-08-12 08:16:00-04:00,MACK,positive
797592.0,UPDATE: Bank of America Downgrades Merrimack Pharmaceuticals Following Series of Disappointing Updates,2013-08-09 10:05:00-04:00,MACK,negative
797593.0,"Bank of America Downgrades Merrimack Pharmaceuticals, Inc. to Neutral, Lowers PO to $6.00",2013-08-09 07:38:00-04:00,MACK,negative
797594.0,"Cowen & Company Downgrades Merrimack Pharmaceuticals, Inc. to Market Perform",2013-08-08 15:11:00-04:00,MACK,neutral
797595.0,"Merrimack Pharmaceuticals, Inc. Reports Q2 EPS of $(0.31) vs $(0.28) Est; Revenue of $18.50M vs $13.68M Est",2013-08-08 08:06:00-04:00,MACK,neutral
797596.0,A Peek Into The Market Before The Trading Starts,2013-07-12 07:15:00-04:00,MACK,neutral
797597.0,Merrimack Prices 5 Share Secondary at $5.00/Share,2013-07-12 06:35:00-04:00,MACK,positive
797598.0,"Market Wrap for Thursday, July 11: Market Jumps on Dovish Bernanke Comments ",2013-07-11 16:14:00-04:00,MACK,neutral
797599.0,"Mid-Day Market Update: PriceSmart Drops On Downbeat Earnings, Alnylam Gains",2013-07-11 13:15:00-04:00,MACK,positive
797600.0,"Mid-Morning Market Update: Markets Surge, Yum! Brands Posts Upbeat Profit",2013-07-11 10:05:00-04:00,MACK,positive
797601.0,Merrimack Announces Proposed Concurrent Public Offerings of Common Stock and Convertible Senior Notes,2013-07-10 16:04:00-04:00,MACK,neutral
797602.0,"Mizuho Securities Initiates Coverage on Merrimack Pharmaceuticals, Inc. at Buy, Announces $12.00 PT",2013-06-25 09:15:00-04:00,MACK,positive
797603.0,"Earnings Scheduled For May 13, 2013 ",2013-05-13 04:34:00-04:00,MACK,neutral
797604.0,Stocks Hitting 52-Week Lows,2013-05-06 10:23:00-04:00,MACK,negative
797605.0,Merrimack Pharmaceuticals' Preclinical Research Shows MM-111 Restores Sensitivity To Chemotherapy And HER2-targeted Treatment In Gastric Cancer Model,2013-04-10 09:03:00-04:00,MACK,negative
797606.0,Merrimack Pharma Files $200M Mixed Securities Shelf,2013-02-01 11:13:00-05:00,MACK,positive
797607.0,Merrimack Pharmaceuticals Spokesperson Says No News Issued by Company to Account for Spike Earlier,2012-10-12 11:01:00-04:00,MACK,negative
797608.0,Merrimack Pharmaceuticals Spikes Higher,2012-10-12 10:45:00-04:00,MACK,neutral
797609.0,"Three Biotech Stocks Analysts Are Keen On (ARIA, MACK, GEVA)",2012-10-03 14:57:00-04:00,MACK,positive
797610.0,Merrimack Pharma Presents Positive Phase 1 Safety and Clinical Results for Cancer Drug,2012-10-02 08:35:00-04:00,MACK,positive
797611.0,"Brean Murray Carret Initiated Coverage on Merrimack Pharmaceuticals at Buy, Announced PT to $12",2012-09-27 09:25:00-04:00,MACK,neutral
797612.0,Benzinga Mid-Afternoon Market Update ,2012-09-25 15:38:00-04:00,MACK,neutral
797613.0,Benzinga Mid-Day Market Update,2012-09-25 12:27:00-04:00,MACK,neutral
797614.0,Benzinga Mid-Morning Market Update,2012-09-25 11:08:00-04:00,MACK,neutral
797615.0,Merrimack Pharma Down Over 20%; Lockup Expired Today,2012-09-25 10:08:00-04:00,MACK,neutral
797616.0,Morning Market Losers,2012-09-25 09:57:00-04:00,MACK,negative
797617.0,Benzinga Mid-Afternoon Market Update ,2012-09-21 15:16:00-04:00,MACK,neutral
797618.0,Benzinga Mid-Day Market Update ,2012-09-21 13:06:00-04:00,MACK,neutral
797619.0,Benzinga Mid-Morning Market Update,2012-09-21 10:41:00-04:00,MACK,neutral
797620.0,Benzinga's Top Initiations,2012-08-31 07:57:00-04:00,MACK,positive
797621.0,"UPDATE: Bank of America Initiates Buy, $13 PO on Merrimack Pharmaceuticals  ",2012-08-31 07:34:00-04:00,MACK,negative
797622.0,"Bank of America Initiates Coverage on Merrimack Pharmaceuticals at Buy, Announces PO of $13",2012-08-31 06:43:00-04:00,MACK,negative
797623.0,Merrimack Pharmaceuticals Receives Positive Mad Money/Jim Cramer Mention -CNBC,2012-07-19 18:30:00-04:00,MACK,positive
797624.0,UPDATE: Oppenheimer Initiates Coverage on Merrimack Pharmaceuticals,2012-05-08 10:50:00-04:00,MACK,neutral
797625.0,UPDATE: J.P. Morgan Initiates Coverage on Merrimack Pharmaceuticals,2012-05-08 10:28:00-04:00,MACK,neutral
797626.0,"Merrimack Pharma IPO Opens for Trading at $7, After Originally Pricing at $7/Share",2012-03-29 10:00:00-04:00,MACK,neutral
797627.0,From EArlier: Merrimack Pharmaceuticals Announces Pricing of Initial Public Offering of 14.3M Shares at $7.00 ,2012-03-29 07:34:00-04:00,MACK,positive
